Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:activeDuring |
gptkb:parathyroid_hormone
|
| gptkbp:administrativeDivision |
inject subcutaneously
|
| gptkbp:availability |
prescription only
|
| gptkbp:clinicalTrials |
Phase 3
improved quality of life published in medical journals positive efficacy results NCT02312345 follow endocrinology guidelines follow endocrinology recommendations improves calcium levels long-term management of hypoparathyroidism ongoing for additional indications supports efficacy and safety |
| gptkbp:community_service |
available on the website
available_through_OPKO_Health,_Inc. |
| gptkbp:contraindication |
hypercalcemia
hypersensitivity to the active ingredient hypocalcemia |
| gptkbp:customerFeedback |
generally positive
|
| gptkbp:date |
FDA_approved
|
| gptkbp:developedBy |
gptkb:OPKO_Health,_Inc.
|
| gptkbp:dosageForm |
solution
|
| gptkbp:drugInterdiction |
available online
none reported subcutaneous absorption stimulates bone and kidney function |
| gptkbp:educationalPrograms |
provided to patients
|
| gptkbp:firstAppearance |
2019-01-15
|
| gptkbp:formulation |
injectable solution
|
| gptkbp:hasCapacity |
available through manufacturer
|
| gptkbp:hasPopulation |
adults and children
|
| gptkbp:healthcare |
important for treatment success
important for understanding treatment important for prescribing consult for dosage adjustments required for long-term use |
| https://www.w3.org/2000/01/rdf-schema#label |
OPKO 900
|
| gptkbp:impact |
as prescribed by a physician
|
| gptkbp:insuranceAccepted |
may vary by plan
|
| gptkbp:is_monitored_by |
calcium levels
|
| gptkbp:launchSite |
daily
|
| gptkbp:mandates |
hypoparathyroidism treatment
|
| gptkbp:manufacturer |
gptkb:OPKO_Health,_Inc.
|
| gptkbp:market |
2019-03-01
|
| gptkbp:marketedAs |
brand name
|
| gptkbp:marketingStrategy |
direct-to-consumer advertising
|
| gptkbp:offers |
varies by pharmacy
|
| gptkbp:packaging |
single-dose vials
|
| gptkbp:patentStatus |
patented
|
| gptkbp:regulatoryCompliance |
approved_by_FDA
|
| gptkbp:research |
funded_by_OPKO_Health,_Inc.
|
| gptkbp:research_areas |
hormone replacement therapy
|
| gptkbp:researchInterest |
with academic institutions
ongoing studies for efficacy |
| gptkbp:route |
subcutaneous injection
|
| gptkbp:safetyFeatures |
generally well tolerated
recommended during treatment |
| gptkbp:sideEffect |
headache
nausea injection site reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:supplyChain |
available in major pharmacies
managed_by_OPKO_Health,_Inc. |
| gptkbp:usedFor |
treatment of hypoparathyroidism
|